Celgene (CELG) says 52-week results demonstrate apremilast produces "meaningful improvements" in ACR scores for patients with psoriatic arthritis. The company will present the data at the European Congress of Rheumatology later today. SA contributor Todd Campbell says the drug "offers upside" for CELG shares and notes that "analysts expect apremilast may generate sales of $300-500M/year." Shares +1.5% premarket.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Tue, 6:33PM)
at Investor's Business Daily (Fri, 6:51PM)
Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blogat Zacks.com (Feb 26, 2015)
at Nasdaq.com (Feb 24, 2015)
at Zacks.com (Feb 23, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs